Mumps: all 83 studies
Page 1 of 1. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of AgeNot yet recruitingNCT07742644Phase 3
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of AgeRecruitingNCT07406360Phase 3
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT07358910
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L VaccinesNot yet recruitingNCT07338851
- Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation PatientsRecruitingNCT07195032Phase 4
- Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated VaccinesNot yet recruitingNCT05952505Phase 4
- Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster VaccinationRecruitingNCT05894395Phase 3
- Induction of Immunity Against Measles in Pediatric Liver Transplant RecipientsRecruitingNCT01770119Phase 4
- A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of AgeCompletedNCT05630846Phase 2Results posted
- Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and InfantsCompletedNCT04398706Phase 2Results posted
- Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) VaccineCompletedNCT02880865Phase 4Results posted
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of AgeCompletedNCT02184572Phase 3Results posted
- Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and OlderCompletedNCT02058563Phase 3Results posted
- Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of AgeCompletedNCT01702428Phase 3Results posted
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of LifeCompletedNCT01681992Phase 3Results posted
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of AgeCompletedNCT01621802Phase 3Results posted
- Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)CompletedNCT01536405Phase 3Results posted
- Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy ChildrenCompletedNCT01506193Phase 3Results posted
- Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese ToddlersCompletedNCT01188343Phase 3Results posted
- ProQuad Dose Selection Study (V221-011)(COMPLETED)CompletedNCT00986232Phase 2Results posted
- A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)CompletedNCT00985166Phase 3Results posted
- Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)CompletedNCT00985153Phase 3Results posted
- Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric VaccinesCompletedNCT00984295Phase 3Results posted
- ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)CompletedNCT00975507Phase 3Results posted
- Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTMCompletedNCT00969436Phase 3Results posted
- Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working SeedsCompletedNCT00892775Phase 2Results posted
- Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of AgeCompletedNCT00861744Phase 2Results posted
- A Study of ProQuad™ in Healthy Children in Korea (V221-023)TerminatedNCT00839917Phase 3Results posted
- Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136CompletedNCT00751348Phase 3Results posted
- Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy ToddlersCompletedNCT00626327Phase 3Results posted
- Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of AgeCompletedNCT00578175Phase 2Results posted
- Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)CompletedNCT00566527Phase 3Results posted
- Safety Study of ProQuad® rHA in Infants (V221-037)CompletedNCT00560755Phase 3Results posted
- Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy ToddlersCompletedNCT00483574Phase 3Results posted
- Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)CompletedNCT00432042Phase 3Results posted
- Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy ToddlersCompletedNCT00422292Phase 3Results posted
- ProQuad® Intramuscular vs SubcutaneousCompletedNCT00402831Phase 3Results posted
- A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy ToddlersCompletedNCT00384397Phase 3Results posted
- Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)CompletedNCT00326183Phase 4Results posted
- V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)CompletedNCT00109343Phase 3Results posted
- A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy AdultsActive, not recruitingNCT06967181Phase 1
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 MonthsCompletedNCT06399003Phase 3
- Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)CompletedNCT06331702Phase 4
- The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School StudentsActive, not recruitingNCT06208683Phase 4
- The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella VaccineStatus unknownNCT05279248Phase 4
- Safety Study of Live Attenuated Mumps Vaccines in Junior High School Students Under 14 Years OldCompletedNCT05145166
- Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy InfantsCompletedNCT05065177Phase 3
- Phase II/III of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Healthy Children Aged 5-11Active, not recruitingNCT04591405Phase 2/3
- Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps VaccineCompletedNCT04364399Phase 4
- MMR at 6 Months TrialCompletedNCT03780179Phase 4
- Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) VaccineCompletedNCT03160820Phase 4
- Phase II of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese InfantsActive, not recruitingNCT03133923Phase 2
- Observational Study to Assess Protection to Mumps in Children Received One-dose Mumps-containing VaccineCompletedNCT02901990
- Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy InfantsCompletedNCT02692599Phase 3
- Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMRCompletedNCT02325310Phase 4
- Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.CompletedNCT01991899Phase 3
- Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)CompletedNCT01874457
- Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose PresentationsCompletedNCT01777529Phase 4
- Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the PhilippinesWithdrawnNCT01738841
- A Phase I, Safety Study of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese ChildrenCompletedNCT01712906Phase 1
- 300 Antibody Diagnostic Test KitStatus unknownNCT01646411
- Special Drug Use Investigation for Botox® (Botulinum) Spasticity (BOTOX is a Registered Trademark of Allergan, Inc.)CompletedNCT01390922
- Making Decisions About the Measles-Mumps-Rubella VaccineCompletedNCT01369394Not applicable
- Measles, Mumps, and Rubella (MMR) Immunity in College StudentsCompletedNCT00962819
- Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable DiseaseStatus unknownNCT00932269
- The Influence of Probiotics on the Immunologic Response to Vaccinations in InfantsStatus unknownNCT00645996Not applicable
- Safety Study of a Refrigerator-stable Formulation of VARIVAX®CompletedNCT00432731Phase 4
- Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)CompletedNCT00432523Phase 3
- Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined VaccineCompletedNCT00406211Phase 3
- Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.CompletedNCT00388440Phase 4
- Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™CompletedNCT00353288Phase 2
- Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™CompletedNCT00352898Phase 2
- Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration RoutesCompletedNCT00351923Phase 3
- Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined VaccineCompletedNCT00313950Phase 4
- Immune Responses to Two Dose Varivax +/- MMR-IITerminatedNCT00258726Phase 1/2
- MMR and Varicella Vaccine in Premature InfantsCompletedNCT00156559
- Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella VaccinesTerminatedNCT00138255
- Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox DiseasesCompletedNCT00127023Phase 3
- Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox DiseasesCompletedNCT00127010Phase 3
- Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox DiseasesCompletedNCT00126997Phase 4
- Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)CompletedNCT00092430Phase 3
- Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)CompletedNCT00092404Phase 2
- A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)CompletedNCT00092391Phase 3